CRISPR Therapeutics AG (CRSP)
|Net Income (ttm)||446.58M|
|Day's Range||94.25 - 97.65|
|52-Week Range||84.38 - 220.20|
|Price Target||159.05 (+66.4%)|
|Est. Earnings Date||Oct 28, 2021|
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate... [Read more...]
Financial PerformanceFinancial Statements
According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 159.05, which is an increase of 66.44% from the latest price.
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company's value isn't reflected in typical performance metrics.
These growth stocks could rebound in a big way.
These two novel-drug makers could be top takeover targets next year.
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serio...
Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) fell just under 10% on Wednesday as the biotech firm presented updated data for the phase 1 trial of its blood cancer candidate CTX 110. RBC Capital main...
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower ...
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies. “We are e...
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year befor...
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+...
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-
Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?
CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.
-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.
A stock market that soured on biotech stocks in general is presenting some bargain opportunities.
These companies could deliver jaw-dropping revenue growth through mid-decade.
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-relate...
If the market crashes these companies could be insulated.
These top seven stocks among Cathie Wood's top holdings are ones investors may be enticed to consider right now. The post 7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio appeared fir...
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Wood is following an important strategy with gene-editing stocks.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.